Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

• A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
  NCT07003074 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 25 locations
• A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
  NCT06962267 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
  NCT06496490 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 25 locations
• A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
  NCT07406035 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 44 locations
• Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
  NCT06754891 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 60 locations
• Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
  NCT06569524 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 53 locations
• TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
  NCT07044908 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 27 locations
• TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
  NCT07047365 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 75 locations
• The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
  NCT06452706 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 16 locations

Common questions

How many trials is Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. recruiting for?

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. is the lead sponsor of 9 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.